EmergingGrowth.com Reports on Orexigen, Behind the Recent Surge
EmergingGrowth.com Reports on Orexigen, Behind the Recent Surge

EmergingGrowth.com, a leading digital financial media company, Reports on Orexigen (NASDAQ: OREX), and its recent surge. Discussion also includes Aetna (NYSE: AET), Abbott Laboratories (NYSE: ABT),  GlaxoSmithKline plc (NYSE: GSK).


Feature your company on EmergingGrowth.com.  Visit EmergingGrowth.com to find out how. 


The biotech industry skyrocketed in 2012 as a result of an increase in the number of new drug approvals. Through September 2012, the US Federal Drug Administration (FDA) approved twenty-two new drugs. There is an improving trend for FDA review approvals and a rise in the rate of new drug approval for rare diseases. Here is a company that is about to get approval for a new drug.

A bio-pharmaceutical company focused on the treatment of obesity, Orexigen Therapeutic Inc (NASDAQ: OREX) has completed phase III clinical trials for Contrave. To fast track the approval process, Orexigen is discussing a faster resubmission path of the New Drug Application (NDA) Contrave with the FDA. When Aetna (NYSE: AET) agreed to provide coverage for the anti-obesity drug, Orexigen shares surged in the market.

The Company's other product candidate, Empatic, has completed Phase II clinical trials. It is a fixed dose combination of two previous drugs used for the treatment of epilepsy , depression, and smoking cessation.  Orexigen developed its own proprietary SR version of the drugs in an effort to improve tolerance for the drug.

“We expect 2013 to be a pivotal year for our company,” said Michael Narachi, Orexigen’s CEO. “US approval of Contrave could come as early as late 2013, and we’re working closely with our North American partner, Takeda, to prepare for commercialization.”

For the three months ended September 30, 2012, Orexigen had $56.1 million in cash and equivalents, and an additional $52.2 million in marketable securities. The company projected the use of $70 million to $75 million in cash in 2012, resulting in a year-end balance of cash, cash equivalent, and marketable securities of between $130 million to $135 million. In October 2012, Orexigen completed a follow-on public offering of common stock raising net proceeds of approximately $56.5 million.

Total operating expenses for the third quarter of 2012 were $31.5 million, compared to $5.4 million for the third quarter of 2011. The increase reflects an increase in research and development expenses associated with the light study of Contrave. The company expects some clinical trial costs originally projected for 2013 to now be incurred in 2012, leading to a commensurate reduction in anticipated clinical trial costs for 2013.

Although procedural details need to be addressed, Orexigen is optimistic that its discussion with the FDA could result in faster path to resubmission of the Contrave NDA.  In November, it announced an update to the projected time frame for completion of enrollment of the  Contrave® clinical trial. Orexigen now expects to complete enrollment of patients required for the interim analysis in the first quarter of 2013, potentially reducing by half the original projections. 

Its competitors are Abbott Laboratories (NYSE: ABT), GlaxoSmithKline plc (NYSE: GSK), and Roche Holding AG (OTC: RHHBY). Trading at a cheap price of about $6 per share and having a market capitalization of $489.54 million, consider putting this company in your watch list. It could turn out to be a solid investment in the near future.




About EmergingGrowth.com


By offering 100% original and unmatched content by the best financial reporters, writers and bloggers in the business, EmergingGrowth.com is emerging as a leading digital financial media portal. Its services provide users, subscribers and advertisers with a variety of content and tools through a range of online, social media, mobile and other mobile outlets.


Since its inception, EmergingGrowth.com has distinguished itself from other financial media companies with its sly approach to reading between the lines in order to locate that needle in the haystack.  Sign up today to see what EmergingGrowth.com has to offer.

NEW:  Feature your company on EmergingGrowth.com.  Find out how by filling out our form at http://emerginggrowth.com/recommend-a-company-to-feature-on-emerging-growth






Join our Linked in Group


Like us on Facebook


All information contained herein as well as on the EmergingGrowth.com website is obtained from sources believed to be reliable but not guaranteed to be accurate or all-inclusive. All material is for informational purposes only, is only the opinion of EmergingGrowth.com and should not be construed as an offer or solicitation to buy or sell securities. In addition, Please make sure you read and understand the Terms of Use, Privacy Policy and the Disclosure posted on the EmergingGrowth.com website. Always remember that investing in securities such as the ones listed within are for high-risk tolerant individuals only and not the general public. Whether you are an experienced investor or not, you should always consult with a stockbroker, financial advisor, or similar before purchasing or selling any securities viewed on any emails sent from EmergingGrowth.com or its website.


SOURCE EmergingGrowth.com

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here